Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine. Show more
Location: 135 Route 202/206, Bedminster, NJ, 07921, United States | Website: https://www.intracellulartherapies.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$131.87
Open
$131.87
Volume
N/A
Day Range
$131.87 - $131.87
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
2.48%
Institutional Own.
96.45%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Caplyta (Lumateperone) Details Bipolar depression, Mental health | Approved Quarterly sales | |
Caplyta (Lumateperone) Details Schizophrenia, Mental health | Approved Quarterly sales | |
Caplyta (Lumateperone) Details Major depressive disorder, Mental health | sNDA Acceptance for review | |
Lumateperone Details Bipolar depression, Mental health | Phase 3 Data readout | |
Lumateperone Details Bipolar Mania | Phase 3 Data readout | |
ITI-1284 Details Agitation in Alzheimer's Disease | Phase 2 Data readout | |
Lenrispodun (ITI-214) (PDE1 inhibitor) Details Heart disease, Parkinson's disease | Phase 2 Data readout | |
ITI-1284 Details Psychosis associated with Alzheimer's Disease | Phase 2 Data readout | |
ITI-1284 (Lumateperone- Deuterated form) Details Alzheimer's disease | Phase 2 Data readout | |
ITI-1284 Details Anxiety Disorders | Phase 2 Initiation | |
LAI (lumateperone long acting injection) Details Mental health, Schizophrenia, Major depressive disorder, Bipolar disease | Phase 1 Data readout | |
Phase 1 Data readout | ||
ITI-333 Details Sleeping disorder, Bipolar depression, Opioid use disorder | Phase 1 Update |